FDA Rule-Making Could Get Makeover Under Obama Administration
This article was originally published in The Pink Sheet Daily
Executive Summary
After GAO finds FDA one of the slower agencies in rulemaking, Rep. Towns asks for timeliness and transparency in White House input on federal regulations.
You may also be interested in...
FDA Risk Communication Research May Follow Critical Path To Avoid OMB
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.